These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 21992802

  • 21. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA, Perni RB.
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [Abstract] [Full Text] [Related]

  • 22. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
    Bogen S, Arasappan A, Pan W, Ruan S, Padilla A, Saksena AK, Girijavallabhan V, Njoroge FG.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4219-23. PubMed ID: 18547808
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
    Lee JC, Yu MC, Lien TW, Chang CF, Hsu JT.
    Assay Drug Dev Technol; 2005 Aug 15; 3(4):385-92. PubMed ID: 16180993
    [Abstract] [Full Text] [Related]

  • 26. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
    Hahm B, Back SH, Lee TG, Wimmer E, Jang SK.
    Virology; 1996 Dec 15; 226(2):318-26. PubMed ID: 8955051
    [Abstract] [Full Text] [Related]

  • 27. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 28. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR, Brandt G, Caillet C, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos L, Leroy F, Liuzzi M, Loi AG, Moulat L, Musiu C, Parsy C, Rahali H, Roques V, Seifer M, Standring D, Surleraux D.
    Bioorg Med Chem Lett; 2015 Sep 15; 25(18):3984-91. PubMed ID: 26231161
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 Sep 15; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 34. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
    Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V.
    J Med Chem; 2007 May 17; 50(10):2310-8. PubMed ID: 17444623
    [Abstract] [Full Text] [Related]

  • 35. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE, El-Bastawissy EE, El-Moselhy TF.
    J Biomol Struct Dyn; 2018 May 17; 36(7):1713-1727. PubMed ID: 28531373
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
    Lasheen DS, Ismail MA, Abou El Ella DA, Ismail NS, Eid S, Vleck S, Glenn JS, Watts AG, Abouzid KA.
    Bioorg Med Chem; 2013 May 15; 21(10):2742-55. PubMed ID: 23583031
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. QSAR and docking studies of HCV NS3 serine protease inhibitors.
    da Cunha EF, Matos KS, Ramalho TC.
    Med Chem; 2013 Sep 15; 9(6):774-805. PubMed ID: 23140577
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.